Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003)
Fabrizio Schifano, John Corkery, Paolo Deluca, Adenekan Oyefeso, A. Hamid Ghodse
Journal of Psychopharmacology March 30, 2006 DOI: 10.1177/0269881106060147 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Descriptive and correlational study Peer reviewed |
|---|---|
| Sample size | 394 |
| Population | UK ecstasy deaths mentions from 1994 to 2003 |
| Duration | 1994 to 2003 |
| Topics | MDMA |
| Keywords | Pharmacology |
| Citations | 96 |
| Key points | Number of ecstasy deaths increased year by year and positively correlated with prevalence of use, number of offenders, and seizures, but negatively correlated with price. |
Abstract
In the last decade, a global trend of escalating ecstasy (MDMA, MDA, MDEA, MBDB) use was observed. Mentions on medical death certificates, last year's ecstasy use, number of drug offenders, seizures, prices and dosage levels figures were used for this descriptive and correlational study. Figures (1994ñ2003) were taken from the UK General Mortality Registers, from the Home Office Statistical Bulletins, from the British Crime Survey and from those reported to both the National Crime Intelligence and Forensic Science Services. A total of 394 ecstasy deaths mentions were here identified from the UK; in 42% of cases ecstasy was the sole drug mentioned. Overall, number of fatalities showed a year-peryear increase and positively correlated with: prevalence of last year's use ( p<0.01); number of offenders ( p<0.01) and number of seizures ( p<0.01) but negatively correlated with ecstasy price ( p<0.05). Price negatively correlated with: prevalence of last year's use ( p<0.001) and number of seizures ( p<0.01); but positively correlated with average MDMA dosage per tablet ( p<0.01). MDA, MDEA and MBDB accounted for a significant proportion of tablets only up to 1997, but not afterwards. Increasing production with a concomitant decrease in ecstasy price may have facilitated an increase in consumption levels and this, in turn, may have determined an increase in number of ecstasy deaths mentions. Only medical death certificates and not coroners' reports at the end of their inquests were here analysed; no data were available in respect of other drugs use and toxicology results.
Citations in the library
Cited by 38
- MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress Journal of Psychopharmacology March 1, 2006
- Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. Journal of Psychopharmacology February 28, 2019
- Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage Current Pharmaceutical Biotechnology June 27, 2010
- Cortisol and 3,4-Methylenedioxymethamphetamine: Neurohormonal Aspects of Bioenergetic Stress in Ecstasy Users Neuropsychobiology 2009
- Mechanism of 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy)‐mediated mitochondrial dysfunction in rat liver PROTEOMICS September 1, 2008
and 33 more in the library
Cites 12
- Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research Human Psychopharmacology: Clinical and Experimental December 1, 2001
- Pharmacology of MDMA in Humans Annals of the New York Academy of Sciences September 1, 2000
- The content of ecstasy tablets: implications for the study of their long‐term effects Addiction December 1, 2002
- Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002 Human Psychopharmacology: Clinical and Experimental September 19, 2003
- MDMA: A Review of Epidemiological Data Journal of Psychoactive Drugs June 1, 2002
and 7 more in the library